RECKITT BENCKIS/S (OTCMKTS:RBGLY) – Equities researchers at Jefferies Financial Group lowered their FY2019 EPS estimates for RECKITT BENCKIS/S in a research note issued to investors on Tuesday, May 7th. Jefferies Financial Group analyst M. Deboo now expects that the company will earn $0.86 per share for the year, down from their previous estimate of $0.87. Jefferies Financial Group has a “Underperform” rating on the stock. Jefferies Financial Group also issued estimates for RECKITT BENCKIS/S’s FY2020 earnings at $0.90 EPS, FY2021 earnings at $0.94 EPS and FY2022 earnings at $0.98 EPS.
Separately, Zacks Investment Research upgraded shares of RECKITT BENCKIS/S from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a research note on Wednesday, March 27th.
About RECKITT BENCKIS/S
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Featured Story: Do Tariffs Work?
Receive News & Ratings for RECKITT BENCKIS/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RECKITT BENCKIS/S and related companies with MarketBeat.com's FREE daily email newsletter.